- Price
- $0.18
- Day
- +2.62%
- Mkt Cap
- $87.94M
- 52W Range
- $0.11 – $3.87
- Volume
- 6.88M
- Beta
- 2.00
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Company will present at the Cantor Global Healthcare Conference to take place on September 9-11, 2026. Cantor Global Healthcare Conference Date / Time: September 9th,.
Read full article
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment
Read full article
SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS) (the “Company” or “Gossamer”), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that it has entered into a securities purchase agreement with certain new and existing institutional investors for a private placement financing.
Read full article
Gossamer Bio, Inc. (Nasdaq: GOSS) (the âCompanyâ or âGossamerâ), a clinical-stage biopharmaceutical company focused on the development and commercializa
Read full article